Fairchild Semiconductor Intl, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Sector
- Technology
- Industry
- Semiconductors
- Address
- IPO Date
- Jan 4, 2016
- CIK
- 0001036960
- Similar Companies
- Business
- Fairchild Semiconductor International, Inc. (FCS) develops, manufactures and markets power analog and discrete semiconductors; non-power semiconductor solutions; and micro-electro-mechanical systems (MEMS)-based products for end markets including industrial, automotive, home appliances, mobile, server and cloud computing, lighting, and consumer electronics. The company offers switching power solutions through its SPS segment, analog power and signal solutions via the APSS segment, and standard products including discretes, rectifiers, diodes, MOSFETs, optocouplers, optoelectronics, SuperFET power MOSFETs, IGBTs, linear regulators, DC/DC converters, PFC and PWM controllers, battery management ICs, data converters, video ICs, LDOs, supervisory circuits, motor ICs, amplifiers, microcontrollers, and interface/logic products; it operates an eight-inch wafer fabrication facility in Bucheon, South Korea, with additional manufacturing and assembly in the United States, Philippines, Malaysia, and China. Founded in 1957 in Santa Clara, California, as a division of Fairchild Camera and Instrument by the "traitorous eight" engineers from Shockley Semiconductor, the company pioneered silicon transistors, the planar process, and integrated circuits, with historical headquarters in San Jose and Sunnyvale, California, and key facilities in South Portland, Maine; Mountaintop, Pennsylvania; West Jordan, Utah; and international sites. Fairchild went public on NASDAQ under ticker FCS in 1999 following its spin-off from National Semiconductor, pursued growth through acquisitions including Raytheon's semiconductor division in 1997, Samsung's power business in 1999, Intersil's discrete power unit in 2001, Impala Linear in 2001, and TranSiC in 2011, and completed its acquisition by ON Semiconductor in September 2016 for $2.4 billion in cash, after which FCS shares ceased active trading, operations integrated into onsemi systems by late 2017 including order fulfillment migration and closure of the West Jordan plant, and the standalone entity now operates as a legacy brand within onsemi's power management portfolio.
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
Esquire Bank Earns Multiple Honors at 2026 FCS Portfolio Awards
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)
Ionis Pharmaceuticals: Promising Growth From Tryngolza Approval
Bowman Acquires Utility Services and Sustainability Solutions Firm FCS Group
Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
Medical Oncologists Elena Kruglyak, MD and Samarth Reddy, MD Join Florida Cancer Specialists & Research Institute
WAYLIVRA▼® (volanesorsen), the First and Only Therapy for FCS, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in England